Posted by Michael Wonder on 21 Aug 2020
BioMarin, Gilead drug rejections don’t signal a change in attitude at the FDA
21 August 2020 - t’s tempting to interpret the FDA’s surprise rejections of drugs from Gilead Sciences and BioMarin Pharmaceutical this week as an agency-wide sentiment downshift, raising concerns that fewer new medicines will reach the market.
Don’t make that mistake.
